# A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients

Study · id `cardio:ct-nct01054092` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01054092](<https://clinicaltrials.gov/study/NCT01054092>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01054092

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 182 participants.

## Technical summary

Registry record NCT01054092. Randomized; no masking; primary purpose treatment. Start 2010-01-14 (actual); primary completion 2011-07-22 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 182 participants (enrolled count; ClinicalTrials.gov record NCT01054092, source copy `cardio:ctgov-nct01054092-2025-05-30`, retrieved 2026-10-26)
- Started: 2010-01-14 (actual) (ClinicalTrials.gov record NCT01054092, source copy `cardio:ctgov-nct01054092-2025-05-30`, retrieved 2026-10-26)
- Primary completion: 2011-07-22 (actual) (ClinicalTrials.gov record NCT01054092, source copy `cardio:ctgov-nct01054092-2025-05-30`, retrieved 2026-10-26)
- Completion: 2011-07-22 (actual) (ClinicalTrials.gov record NCT01054092, source copy `cardio:ctgov-nct01054092-2025-05-30`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01054092, source copy `cardio:ctgov-nct01054092-2025-05-30`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01054092-2025-05-30`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): ipragliflozin
- Lead sponsor: Astellas Pharma Inc
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Astellas Pharma Inc (`cardio:org-astellas-pharma-inc`)

## Provenance

Content hash: 05f32eb7effed2ae90c5ee2f649bbe83eab26e07ac185e9db1933935dabdfbfa
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
